Nuclear waste plans enter critical phase
Article Abstract:
The nuclear power industry of Great Britain faces difficulty in the disposal of large amounts of radioactive waste and in convincing the public about the safety of its disposal plans. Nirex, the industry's waste disposal company, demands for laboratory facilities to assess the suitability of rocks for a deep repository for waste. Cumbria County Council suspects the desirability of the company's plans of disposal and demands for convincing evidence. The absence of any independent mechanism to assess Nirex's research plans contributes to the suspicion.
Publication Name: Nature
Subject: Zoology and wildlife conservation
ISSN: 0028-0836
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Troubled UK biotech firm faces new probe
Article Abstract:
British Biotech will undergo further investigations by the London Stock Exchange after details were revealed about its handling of sensitive clinical data. The US Securities and Exchange Commission decided to investigate the accuracy of statements concerning the company's marimastat anticancer drug. The company's share price has fallen to less than 0.50 pence, reducing its value to 330 million pounds sterling, following these developments and the recent sacking of director of clinical research, Andrew Miller.
Publication Name: Nature
Subject: Zoology and wildlife conservation
ISSN: 0028-0836
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Nuclear triggers get subcritical scrutiny. Research 'could still result in nuclear arms', warns experts. Lab rejects report that nuclear dump 'could explode.'
- Abstracts: Labour party pledges to end privatization of UK laboratories. UK Labour Party seeks votes through pro-science image
- Abstracts: Multi-species plan for forest habitat. Good news for owls and jobs. Red Hills salamander HCP
- Abstracts: Genome ethics panel comes under the microscope at NIH. Investment analysts paint rosy prospect for biotech